...
首页> 外文期刊>Journal of Emergencies, Trauma and Shock >Comparing the efficacy and safety of two regimens of sequential systemic corticosteroids in the treatment of acute exacerbation of bronchial asthma
【24h】

Comparing the efficacy and safety of two regimens of sequential systemic corticosteroids in the treatment of acute exacerbation of bronchial asthma

机译:比较序贯全身性皮质类固醇的两种方案治疗支气管哮喘急性加重的疗效和安全性

获取原文

摘要

Background:Corticosteroids are commonly used in the management of acute asthma. However, studies comparing various steroids in the management of acute asthma are lacking.Objective:To compare the efficacy and safety of two treatment regimens – intravenous (IV) methylprednisolone (MP) followed by oral MP and IV hydrocortisone (HC) followed by oral prednisolone in acute bronchial asthma patients.Materials and Methods:This was a randomized, prospective study performed in the emergency department (ED) of a tertiary care hospital in North India. A total of 94 patients with acute asthma were randomly allocated to either of the two treatment groups: Group A (n = 49) or Group B (n = 45). Patients in Group A were administered HC 200 mg IV 6-hourly until discharge from the ED, followed by oral prednisolone 0.75 mg/kg daily for 2 weeks. Patients in Group B were administered MP 125 mg IV bolus, followed by 40 mg MP IV 6-hourly until discharge, and then oral MP 0.6 mg/kg daily for 2 weeks. All clinical variables, peak expiratory flow (PEF) and forced expiratory volume in one second (FEV1) were assessed at baseline, at 1, 3 and 6 h and at every 6 h thereafter until discharge from the ED. The patients were followed-up after 2 weeks of discharge. The response to treatment was assessed by clinical and spirometric evaluation. Independent t-tests and chi-square tests were used to compare the two treatment regimens.Results:The baseline characteristics were comparable in the two groups. There was a significant improvement in PEF and FEV1 within the groups at 2 weeks of treatment when compared to the baseline. At 2 weeks of follow-up, Group B showed significant improvement over Group A in PEF (P < 0.0001), FEV1 (P < 0.0001) and asthma score (P = 0.034). There was a significant increase in the blood sugar value at 2 weeks in both the groups. However, the increase was greater in Group A as compared to Group B (P < 0.0001).Conclusion:This study suggests that in acute asthma patients, IV MP followed by oral MP is a more efficacious and safer treatment regimen than IV HC followed by oral prednisolone.
机译:背景:糖皮质激素常用于急性哮喘的治疗。但是,尚缺乏比较各种类固醇在急性哮喘治疗中的研究。目的:比较两种治疗方案的疗效和安全性–静脉(IV)甲基泼尼松龙(MP),然后口服MP和IV氢化可的松(HC),然后口服泼尼松龙材料和方法:这是在印度北部一家三级护理医院急诊科(ED)中进行的一项随机,前瞻性研究。将总共​​94例急性哮喘患者随机分配到两个治疗组中的任何一个:A组(n = 49)或B组(n = 45)。 A组患者每6小时静脉注射HC 200 mg,直到从ED出院,然后每天口服强的松龙0.75 mg / kg,持续2周。 B组患者接受MP 125毫克静脉推注,然后每6小时一次MP 40毫克静脉推注直至出院,然后每天口服MP 0.6毫克/千克,持续2周。在基线,1、3和6小时以及此后每6小时评估一次所有的临床变量,最大呼气流量(PEF)和一秒钟的强制呼气量(FEV1),直到从ED出院。出院2周后对患者进行随访。通过临床和肺活量评估评估对治疗的反应。采用独立的t检验和卡方检验比较两种治疗方案。结果:两组的基线特征相当。与基线相比,治疗2周时各组的PEF和FEV1有显着改善。随访2周时,B组的PEF(P <0.0001),FEV1(P <0.0001)和哮喘评分(P = 0.034)较A组有显着改善。两组在第2周的血糖值均显着增加。然而,与B组相比,A组的增加更大(P <0.0001)。结论:本研究表明,在急性哮喘患者中,IV MP联合口服MP比IV HC联合联合化疗更有效,更安全口服泼尼松龙。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号